Effect of Atorvastatin in the management of COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20150221021159N7
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age 18 years or older
Diagnosis of COVID-19 by RT PCR test and CT scan of the lung and the opinion of the specialist physician
Hospitalization in the intensive care unit
Full consent and acceptance of the patient or their legal guardian to recruit in the study
Possibility to follow the patient for at least 7 days

Exclusion Criteria

Contraindications to the use of atorvastatin include allergic reactions to the drug, active liver disease or persistent and unexplained increase in liver enzymes, pregnancy and lactation, severe hepatic or renal insufficiency (clcr <30 ml / min)
Malignancy or underlying immunodeficiency or concomitant use of immunosuppressive drugs
Intubated patient under care with mechanical ventilation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical improvement of COVID-19. Timepoint: Day: 1, 3, 7 and 14. Method of measurement: APACHE score, evaluation of vital signs? relevant laboratory and arterial blood gas analysis.